AEMD Stock Price: Over 290% Increase Pre-Market Explanation

By Amit Chowdhry ● June 9, 2021
  • The stock price of Aethlon Medical, Inc. (NASDAQ: AEMD) increased by over 290% pre-market today. This is why it happened.

The stock price of Aethlon Medical, Inc. (NASDAQ: AEMD) increased by over 290% pre-market today. Investors have been responding positively to the company recently announcing the publication of a pre-print manuscript highlighting 2 case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier. Both of the patients were given access to Hemopurifier treatment through Emergency Use. 

The manuscript is titled “Removal of COVID-19 Spike Protein, Whole Virus, Exosomes and Exosomal microRNAs by the Hemopurifier Lectin-Affinity Cartridge in Critically Ill Patients with COVID-19 Infection” and it was published in Research Square.

The Hemopurifier is a cartridge that was designed to filter viruses and exosomes from the blood. And the manuscript describes the use of the Hemopurifier for a total of 9 sessions in 2 critically ill COVID-19 patients. 

In the first case, there was improvement in COVID-19 associated coagulopathy (CAC), lung injury, inflammation, and tissue injury despite the absence of demonstrable COVID-19 viremia (having demonstrated strong viremia earlier in the patient’s disease cycle), indicating that the removal of exosomes contributed to the patient’s recovery. This patient received 8 Hemopurifier treatments without complications and eventually was weaned from a ventilator and was discharged from the hospital.

And the second case featured the first-ever demonstration of in vivo removal of SARS-CoV-2 virus from the bloodstream of an infected patient. And the patient completed a 6 hour Hemopurifier treatment without complications and subsequently was placed on Continuous Renal Replacement Therapy (CRRT). This patient ultimately expired 3 hours after being placed on CRRT because of the advanced stage of the disease.

After this news was announced, Aethlon Medical was initiated with a “Buy” rating at H.C. Wainwright. And H.C. Wainwright analyst Vernon Bernardino had assigned the company a $5 price target. Bernardino noted that Hemopurifier’s success with the viral infection program would be an early indication of high potential for successful application in the oncology program.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.